Health & Medicinearticle2026-09-22

Correlation of apparent diffusion coefficient, FAP expression in IHC and [68Ga]Ga‑FAPI‑46 uptake using integrated PET/MRI in high-grade soft tissue sarcoma: initial exploratory results

Open access0 citations

Abstract

Abstract Background Fibroblast activation protein inhibitor (FAPI)-targeted positron emission tomography (PET) has emerged as a promising imaging approach in soft tissue sarcomas (STS), whereas magnetic resonance imaging (MRI) remains the diagnostic standard. We evaluated integrated [ 68 Ga]Ga‑FAPI‑46 PET/MRI including maximum standard uptake value (SUV max ), diffusion-weighted imaging, apparent diffusion coefficient (ADC), and contrast-enhanced sequences compared to FAP expression in immunohistochemistry for tumor assessment in high-grade STS. Results Thirteen [ 68 Ga]Ga‑FAPI‑46 PET/MRI examinations from 9 patients were included, of which 4 were follow-up scans after therapy. All STS showed distinct FAPI uptake (median SUV max 8.4; range 2.9–33). Mean SUV max was 13 (2.9–33) for G2 and 8.4 (7.5–8.4) for G3 tumors. Neither SUV max ( P = 0.196) nor ADC ( P = 0.895) differentiated between FNCLCC Grade 2 and Grade 3. A significant inverse correlation was observed between ADC mean and SUV max (Spearman’s ρ = −0.70, 95% CI: −0.93 to − 0.07, P = 0.035). Immunohistochemistry demonstrated positive FAP expression in 4 of 9 patients, with significantly higher SUV max in FAP-positive vs. negative tumors in immunohistochemistry (17.7 vs. 6.4; P = 0.047). High concordance of [ 68 Ga]Ga-FAPI-46 uptake and contrast enhancement was observed. Treatment responders showed marked reductions in SUV max (40–70%) and increased ADC without significant changes in tumor size. Conclusion In this exploratory pilot study, [68Ga]Ga-FAPI-46 PET/MRI provided complementary functional information in high-grade STS. Although no correlation with grading was observed either using SUVmax or ADC, a significant inverse correlation between ADCmean and SUVmax was identified within this cohort. Preliminary observations regarding treatment monitoring suggested that early changes in tracer uptake and ADC may reflect treatment-related changes, however, these findings were derived from a small pilot cohort. Larger prospective studies are required to validate these observations and to further define the potential role of [68Ga]Ga-FAPI-46 PET/MRI in treatment monitoring and response assessment.

// Source

View paper (DOI)Open access versionOpenAlexEJNMMI ResearchPublished 2026-09-22

Authors: Madelaine Hettler, Franka Menge, Johannes Ludwig, Dominik Nörenberg, Stefan O. Schönberg, Anna Hinterberger, Björn Wängler, Carmen Wängler, Henning Rudolf, Güllü Davarci, Patrick Cieslik, Cristina L. Cotarelo, Melissa Harbrücker, Christoph Reißfelder, Jens Jakob, Wolfgang G. Kunz, Freba Grawe